
Your Feed
Iberdomide Combos Post-ASCT in Myeloma: Eliminating Residual Disease (COMMANDER)
Mezigdomide in New Combos: Early Results for Relapsed/Refractory Myeloma
MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24
MRD Progress in Newly Diagnosed #Myeloma, Quad Induction Therapy and ASCT |Luciano Costa, MD| #ASH24
A New Standard: Blinatumomab + Chemo in Childhood Acute Lymphoblastic Leukemia | Rachel Rau | #ASH24
Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24
Understanding the Role of Magnesium for Myeloma Patients | Urvi Shah, MD | #ASH24
Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24
Daratumumab for Patient with High-risk Smoldering Myeloma | Rahul Banerjee | #ASH24
Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24
Improving MGUS Care through Collaborative Models and Community-Based Support | Beth Faiman, CNP, PhD | #ASH24
Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24
Talquetamab in Myeloma: Results from HealthTree Qualitative Research | Beth Faiman, CNP, PhD | #ASH24
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24
Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD | #ASH24
Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24
Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD | #ASH24